Monoclonal antibody involved in carcinoma invasion, with high potential as a therapeutic target.
| Inventor | Institute |
|---|---|
| John Marshall | Queen Mary University of London |
| Cat. #: | 151543 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Cell signaling and signal transduction;Stem cell biology;Tissue-specific biology |
| Application: | FACS ; IF ; IP ; Fn |
| Target: | Integrin alpha v/beta 6 |
| Reactivity: | Human |
| Clone: | AvB6 53a.2 |
| Host: | Rat |
| Class: | Monoclonal |
| Product description: | Monoclonal antibody involved in carcinoma invasion, with high potential as a therapeutic target. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Immunogen: | Mouse fibroblasts retrovirally infected with cDNA to human beta6 (3T3b6.19). Cells expressed a mouse/human avb6 chimera. |
| Immunogen Uniprot ID: | P06756 |
| Target background: | Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells and aberrant integrin expression has been found in many epithelial tumours. The alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. Integrin alpha-v beta-6 is upregulated in cancers and during tissue remodelling but is absent from resting adult tissues. Integrin alpha-v beta-6 promotes carcinoma invasion, fibrosis and correlates with poor survival and therefore makes a promising therapeutic target. This antibody does not recognize alpha V or other alpha V integrins. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Liu et al. 2017. Exp Ther Med. 14(4):3880-3886. PMID: 29042996. Marsh et al. 2008. Cancer Res. 68(9):3295-303. PMID: 18451156. alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.